Contributed Abstracts
Hall 1 (Salt Palace Convention Center)
Single Institution Review of Allogeneic Bone Marrow Transplantation for Multiple Myeloma: An 18 Year Experience
Abdul M Adjei, MD, Fox Chase Cancer center;
Vinit Karur, MD, PhD, Fox chase Cancer cencter;
Joseph Vadakara, MD, Fox Chase cancer center;
C J Fidler, Abington Cancer Care Specialists;
Neel Gandhi, MD, Fox Chase Cancer Center;
Manish Sharma, MD, Temple University;
Thomas Klumpp, MD, Temple University Bone Marrow Transplant Program;
Omotayo Fasan, MD, Temple university Bone Marrow transplant program;
Mary Ellen Martin, MD, Temple University;
Patricia Lamont Kropf, MD, Temple Fox Chase Bone Marrow Trans;
Kenneth F. Mangan, MD, Temple University BMT Program
The Impact of Sarcopenia On Transplant-Related Outcomes in Patients with Non-Hodgkin's and Hodgkin's Lymphoma
Megan Veresh Caram, MD, University of Michigan;
Emily Light Bellile, MS, University of Michigan;
Michael Englesbe, MD, University of Michigan;
Michael Terjimanian, MS, University of Michigan;
Christopher Sonnenday, MD, MHS, University of Michigan;
Jennifer Jane Griggs, MD, MPH, University of Michigan;
Daniel R. Couriel, M.D., University of Michigan
Long-Term Outcomes of Patients with Systemic Light Chain Amyloidosis (AL) Treated At Diagnosis with Risk-Adapted Stem Cell Transplant and Consolidation with Novel Agents
Heather Landau, MD, TBD;
Daniel Fein, SUNY Downstate;
Hani Hassoun, MD, Memorial Sloan-Kettering Cancer Center;
Christina Bello, Memorial Sloan-Kettering Cancer Center;
Joanne Chou, Memorial Sloan-Kettering Cancer Center;
Sean Devlin, PhD, Memorial Sloan-Kettering Cancer Center;
Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Raymond Comenzo, MD, Tufts Medical Center
Increased Number of Prior Therapies and/or Use of Mismatched Unrelated Donors Adversely Affect Allogeneic Hematopoietic Cell Transplantation (alloHCT) Outcomes in Relapsed/Refractory Hodgkin Lymphoma (HL)
Asmita Mishra, MD, H. Lee Moffitt Cancer Center;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center;
Ernesto Ayala, H. Lee Moffitt Cancer Center;
Hugo Fernandez, MD, H. Lee Moffitt Cancer Center;
Teresa Field, MD PhD, H. Lee Moffitt Cancer Center;
Mohamed Kharfan-Dabaja, H. Lee Moffitt Cancer Center;
Frederick Locke, H. Lee Moffitt Cancer Center;
Taiga Nishihori, MD, H. Lee Moffitt Cancer Center;
Lia Perez, H. Lee Moffitt Cancer Center;
Marcie Tomblyn, MD, MS, H. Lee Moffitt Cancer Center
Extremely High Incidence of CMV-pp65 Antigenemia in ATLL Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Nobuaki Nakano, MD, Imamura Bun-in Hospital;
Ayumu Kubota, MD, Imamura Bun-in Hospital;
Mashahito Tokunaga, MD, Imamura Bun-in Hospital;
Shogo Takeuchi, MD, Imamura Bun-in Hospital;
Yoshifusa Takatsuka, MD, Imamura Bun-in Hospital;
Atae Utsnomiya, MD, PhD, Imamura Bun-in Hospital
Stem Cell Mobilization Using the Combination of GCSF (G) and Plerixafor (P) for Lymphoma Patients (pts) Can Overcome the Poor Prognostic Factors That Impact Mobilization Per GITMO Criteria
Sunita Nathan, MD, Rush University Medical Center;
John Maciejewski, MD, PhD, Rush University Medical Center;
Elizabeth Rich, MD, PhD, Rush University Medical Center;
Reem Karmali, MD, Rush University Medical Center;
Parameswaran Venugopal, MD, Rush University Medical Center;
Stephanie A. Gregory, MD, Rush University Medical Center;
Henry C Fung, MD, Rush University Medical Center
Phase 2 Study of Allogeneic Hematopoietic Cell Transplant (HCT) Following Intermediate-Intensity Fludarabine and Busulfan x 4 (FluBu4) Conditioning for High-Risk or Advanced Multiple Myeloma
Attaphol Pawarode, M.D., University of Michigan;
Shin Mineishi, M.D., University of Michigan;
Thomas Braun, Ph.D., University of Michigan School of Public Health;
James L.M. Ferrara, M.D., D.Sc., University of Michigan;
John Magenau, M.D., University of Michigan;
Edward Peres, M.D., University of Michigan;
Gregory Yanik, M.D., University of Michigan;
Pavan Reddy, M.D., University of Michigan;
John E Levine, M.D., M.S., University of Michigan;
Sung Won Choi, M.D., University of Michigan;
Carrie L. Kitko, M.D., University of Michigan;
Andrew C. Harris, M.D., University of Michigan;
James A Connelly, M.D., University of Michigan;
Steven C. Goldstein, M.D., University of Michigan;
Daniel R. Couriel, M.D., University of Michigan
Matched Pair Analysis of Efficacy and Toxicity of Conditioning BEAM and Busilvex Based Regimen in Autologous Hematopoietic Cell Transplantation for Lymphomas: Preliminary Results
Ioanna Sakellari, George Papanicolaou Hospital;
Despina Mallouri, George Papanicolaou Hospital;
Damianos Sotiropoulos, George Papanicolaou Hospital;
Ioannis Batsis, George Papanicolaou Hospital;
Varnavas Konstantinou, George Papanicolaou Hospital;
Mihail Iskas, George Papanicolaou Hospital;
Panayiotis Baliakas, George Papanicolaou Hospital;
Kyriakos Karypidis, George Papanicolaou Hospital;
Elissavet Georgiadou, George Papanicolaou Hospital;
Vasiliki Douka, George Papanicolaou Hospital;
Eleni-Maria Abela, George Papanicolaou Hospital;
Anastasia Marvaki, George Papanicolaou Hospital;
Chrysa Apostolou, George Papanicolaou Hospital;
Evaggelia Yannaki, George Papanicolaou Hospital;
Panayiotis Kaloyannidis, George Papanicolaou Hospital;
Achilles Anagnostopoulos, MD, George Papanicolaou Hospital
Allogeneic Stem-Cell Transplantation in Hodgkin Lymphoma; A More Favorable Outcome in Patients with Chemo-Sensitive Disease and with Treosulfan-Based Conditioning
Avichai Shimoni, MD, Chaim Sheba Medical Center;
Ronit Yerushalmi, MD, Chaim Sheba Medical Center;
Noga Shem-Tov, MD, Chaim Sheba Medical Center;
Yulia Volchek, MD, Chaim Sheba Medical Center;
Abraham Avigdor, MD, Chaim Sheba Medical Center;
Arnon Nagler, MD, Chaim Sheba Medical Center
Mechanistic Studies of the Synergistic Cytotoxicity of Clofarabine and Gemcitabine in Multiple Myeloma Cell Lines: Relevance of p53-Status
Ben Valdez, PhD, UT MD Anderson Cancer Center;
Guiyun Wang, PhD, U. T. M. D. Anderson Cancer Center;
David Murray, PhD, Cross Cancer Institute;
Yago Nieto, MD, PhD, The Univ of Texas MD Anderson Cancer Ctr;
Yang Li, MS, U. T. M. D. Anderson Cancer Center;
Muzaffar Qazilbash, MD, UT MD Anderson Cancer Center;
Richard E. Champlin, MD, MD Anderson Cancer Center;
Borje S. Andersson, MD, PhD, M. D. Anderson Cancer Center
Lenalidomide Could Minimize an Engraftment Syndrome After Autologous Hematopoietic Stem Cell Transplantation in Patients with POEMS Syndrome
Junichiro Yuda, Kyushu University Graduate School of Medical Science;
Koji Kato, Kyushu University Graduate School of Medical Science;
Katsuto Takenaka, Kyushu University Graduate School of Medical Science;
Masayasu Hayashi, Kyushu University Graduate School of Medical Science;
Shingo Urata, Kyushu University Graduate School of Medical Science;
Shuichiro Takashima, Kyushu University Graduate School of Medical Science;
Yoshikane Kikushige, Kyushu University Graduate School of Medical Science;
Kazuki Tanimoto, Kyushu University Graduate School of Medical Science;
Hiromi Iwasaki, Kyushu University Graduate School of Medical Science;
Toshihiro Miyamoto, Kyushu University Graduate School of Medical Science;
Takanori Teshima, Kyushu University Graduate School of Medical Science;
Koichi Akashi, Kyushu University Graduate School of Medical Science
![[Visit Client Website]](images/banner.gif)